Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
PurposeTo investigate whether progression-free survival (PFS) or time to progression (TTP) could be a valid surrogate endpoint for overall survival (OS) in patients with limited-stage small-cell lung cancer (LS-SCLC) receiving combined chemoradiotherapy.MethodsLiterature searching was performed in P...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.810580/full |
| _version_ | 1798036808628436992 |
|---|---|
| author | Yin Yang Jianyang Wang Wenqing Wang Tao Zhang Jingjing Zhao Yu Wang Yexiong Li Luhua Wang Nan Bi |
| author_facet | Yin Yang Jianyang Wang Wenqing Wang Tao Zhang Jingjing Zhao Yu Wang Yexiong Li Luhua Wang Nan Bi |
| author_sort | Yin Yang |
| collection | DOAJ |
| description | PurposeTo investigate whether progression-free survival (PFS) or time to progression (TTP) could be a valid surrogate endpoint for overall survival (OS) in patients with limited-stage small-cell lung cancer (LS-SCLC) receiving combined chemoradiotherapy.MethodsLiterature searching was performed in PubMed, Embase, and The Cochrane Library up to 2021. Prediction models were firstly established using data from phase III randomized controlled trials (RCTs) and then externally validated in phase II and retrospective studies. Correlation analysis was evaluated by a weighted linear regression model at both trial and arm levels. Cross-validation was performed to assess the consistency and robustness of the established models.Results37 studies, including 15 phase III RCTs, 12 phase II studies, and 10 retrospective studies, were selected in the final analysis. In trial-level surrogacy, a very good correlation was observed between hazard ratios (HRs) of PFS/TTP and OS (R2 = 0.783, 95% CI 0.771–0.794). In arm-level surrogacy, very good correlations were also observed between 2-year (R2 = 0.823, 95% CI 0.814–0.832), 3-year (R2 = 0.843, 95% CI 0.833–0.850), 5-year (R2 = 0.852, 95% CI 0.843–0.859) PFS/TTP, and 5-year OS. An excellent correlation was observed between 4-year PFS/TTP and 5-year OS (R2 = 0.906, 95% CI 0.901–0.910). Cross-validation demonstrated reasonable overall consistency. External validation in phase II and retrospective studies showed good agreement (R2, 0.728–0.824).ConclusionsPFS/TTP was a valid surrogate endpoint for OS in patients with LS-SCLC receiving combined chemoradiotherapy. The finding provides high-level evidence to support PFS/TTP as the primary endpoint in clinical trials so as to speed up introducing novel agents to the treatment of LS-SCLC. |
| first_indexed | 2024-04-11T21:18:05Z |
| format | Article |
| id | doaj.art-e9ca2bc0bf1e47439e1d09ce7ea5f897 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T21:18:05Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e9ca2bc0bf1e47439e1d09ce7ea5f8972022-12-22T04:02:46ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-01-011210.3389/fonc.2022.810580810580Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-AnalysisYin Yang0Jianyang Wang1Wenqing Wang2Tao Zhang3Jingjing Zhao4Yu Wang5Yexiong Li6Luhua Wang7Nan Bi8Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaPurposeTo investigate whether progression-free survival (PFS) or time to progression (TTP) could be a valid surrogate endpoint for overall survival (OS) in patients with limited-stage small-cell lung cancer (LS-SCLC) receiving combined chemoradiotherapy.MethodsLiterature searching was performed in PubMed, Embase, and The Cochrane Library up to 2021. Prediction models were firstly established using data from phase III randomized controlled trials (RCTs) and then externally validated in phase II and retrospective studies. Correlation analysis was evaluated by a weighted linear regression model at both trial and arm levels. Cross-validation was performed to assess the consistency and robustness of the established models.Results37 studies, including 15 phase III RCTs, 12 phase II studies, and 10 retrospective studies, were selected in the final analysis. In trial-level surrogacy, a very good correlation was observed between hazard ratios (HRs) of PFS/TTP and OS (R2 = 0.783, 95% CI 0.771–0.794). In arm-level surrogacy, very good correlations were also observed between 2-year (R2 = 0.823, 95% CI 0.814–0.832), 3-year (R2 = 0.843, 95% CI 0.833–0.850), 5-year (R2 = 0.852, 95% CI 0.843–0.859) PFS/TTP, and 5-year OS. An excellent correlation was observed between 4-year PFS/TTP and 5-year OS (R2 = 0.906, 95% CI 0.901–0.910). Cross-validation demonstrated reasonable overall consistency. External validation in phase II and retrospective studies showed good agreement (R2, 0.728–0.824).ConclusionsPFS/TTP was a valid surrogate endpoint for OS in patients with LS-SCLC receiving combined chemoradiotherapy. The finding provides high-level evidence to support PFS/TTP as the primary endpoint in clinical trials so as to speed up introducing novel agents to the treatment of LS-SCLC.https://www.frontiersin.org/articles/10.3389/fonc.2022.810580/fulllimited-stage small-cell lung cancersurrogate endpointoverall survivalprogression-free survivaltime to progressionchemoradiotherapy |
| spellingShingle | Yin Yang Jianyang Wang Wenqing Wang Tao Zhang Jingjing Zhao Yu Wang Yexiong Li Luhua Wang Nan Bi Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis Frontiers in Oncology limited-stage small-cell lung cancer surrogate endpoint overall survival progression-free survival time to progression chemoradiotherapy |
| title | Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis |
| title_full | Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis |
| title_fullStr | Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis |
| title_short | Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis |
| title_sort | progression free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited stage small cell lung cancer a systematic review and meta analysis |
| topic | limited-stage small-cell lung cancer surrogate endpoint overall survival progression-free survival time to progression chemoradiotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.810580/full |
| work_keys_str_mv | AT yinyang progressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT jianyangwang progressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT wenqingwang progressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT taozhang progressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT jingjingzhao progressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT yuwang progressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT yexiongli progressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT luhuawang progressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT nanbi progressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis |